What is the cardioprotective role of hormone replacement therapy?

被引：9

作者：

Howard N. Hodis

Wendy J. Mack

Roger Lobo

机构：

[1] Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA 90033

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Atherosclerosis; Raloxifene; Arterioscler Thromb Vasc Biol; Subclinical Atherosclerosis; Atherosclerosis Progression;

D O I：

10.1007/s11883-003-0069-z

中图分类号：

学科分类号：

摘要：

A very large body of literature has yielded strong biologic and mechanistic plausibility for the consistent observational findings that estrogen is cardioprotective. Recently completed randomized, controlled trials have been interpreted as challenging the doctrine that hormone replacement is cardioprotective for postmenopausal women. However, other than the Estrogen in the Prevention of Atherosclerosis Trial, none of the currently completed (and no ongoing) randomized, controlled trials have appropriately tested the hypothesis generated from observational data that estrogen replacement is cardioprotective. This mainly results from the fact that randomized, controlled trials have not tested the same pattern and type of hormone use in the same population of women observed in the epidemiologic studies. On the other hand, recently completed randomized, controlled trials provide important but limited information concerning the clinical use of a specific regimen of hormone replacement for the prevention of cardiovascular disease in a particular population of postmenopausal women. Observations made from epidemiologic studies will have to be appropriately tested in randomized, controlled trials before any real conclusions can be drawn as to whether hormone replacement is cardioprotetive. Copyright © 2003 by Current Science Inc.

引用

页码：56 / 66

页数：10

共 49 条

[1]

Grodstein F., Stampfer M., The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women, Prog. Cardiol. Dis., 38, pp. 199-210, (1995)

[2]

Grodstein F., Stampfer M., Estrogen for women at varying risk of coronary disease, Maturitas, 30, pp. 19-26, (1998)

[3]

Archer D.F., Pickar J.H., Bottiglioni F., Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate, Obstet. Gynecol., 83, pp. 686-692, (1994)

[4]

Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E., Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women, Obstet. Gynecol., 84, pp. 987-995, (1994)

[5]

Hulley S., Grady D., Bush T., Et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart-disease in postmenopausal women, JAMA, 280, pp. 605-613, (1998)

[6]

Grady D., Herrington D., Bittner V., Et al., Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II), JAMA, 288, pp. 49-57, (2002)

[7]

Herrington D.M., Reboussin D.M., Brosnihan K.B., Et al., Effects of estrogen replacement on the progression of coronary artery atherosclerosis, N. Engl. J. Med., 343, pp. 522-529, (2000)

[8]

Design of the Women's Health Initiative Clinical Trial and Observational Study: The Women's Health Initiative Study Group, Controlled Clinical Trials, 19, pp. 61-109, (1998)

[9]

Risks and benefits of estrogen plus progestin in healthy menopausal women: Principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, pp. 321-333, (2002)

[10]

Angerer P., Stork S., Kothny W., Et al., Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized controlled trial, Arterioscler. Thromb. Vasc. Biol., 21, pp. 262-268, (2001)

← 1 2 3 4 5 →